Latest News
BrightFocus-funded projects get at the root of capillary stalling in Alzheimer’s disease, which reduces brain blood flow and increases risk for dementia. Evidence from mice suggests it’s not driven by diet and obesity alone, and a targeted treatment could help.
Early research shows one can prevent loss of brain nerve cell communication in Alzheimer’s disease by blocking ‘caspase’ from making toxic amyloid-beta from APP.
BrightFocus Foundation is partnering with the National Institute of Health’s (NIH’s) National Institute of Neurological Disorders and Stroke (NINDS) to fund an innovative research grant to develop retinal scans to identify early signs of vascular contributions to cognitive dementia (VCID), one of the leading causes of memory loss.
Learn how to decrease your risk of developing Alzheimer's disease, if statins increase or decrease Alzheimer's risk, new ideas to fight tau tangles, the BrightFocus-funded research of Nick Cochran, PhD, who is working to find out how an important gene for Alzheimer’s disease, called MAPT, is turned on in neurons, and more in the spring 2020 edition of Alzheimer's Disease Research Review.
Learn about a BrightFocus-funded researcher who is exploring the biology that connects Alzheimer’s disease and Parkinson's disease.
Learn about research that is exploring how to block the assembly of the tau protein, one of the hallmarks of Alzheimer's disease.
A BrightFocus Foundation-funded project to develop a blood-based screening test for Alzheimer’s disease has passed proof of concept stage and C2N Diagnostics, the company spearheading the development of the test, will move forward to approve use in research and clinical settings, according to a presentation at a major scientific conference.
BrightFocus Foundation today announced that it has received a SHORTY Social Good Award® for the public impact of its nationwide screening tour of Turning Point, a documentary by acclaimed filmmaker James Keach.
In a new Gates Notes, philanthropist Bill Gates outlined the great challenges facing scientists in the search for better treatments, and ultimately a cure, for Alzheimer’s disease.
BrightFocus is highly encouraged by Biogen’s announcement today that clinical trials of its experimental drug aducanumab reduced cognitive decline in some Alzheimer’s patients through improved cognition, memory, and activities of daily living.